PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

Condition:   Colon Cancer Interventions:   Drug: Panitumumab;   Drug: Nivolumab;   Drug: Ipilimumab Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Amgen;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials